0IMT.LSE

Photocure ASA

0IMT.LSE, UK

Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, pharmacies, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

https://www.photocure.com

Stock Price

NOK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.07

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

0.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

0.57 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

15.41 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.43

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Photocure ASA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

—

EPS Actual

—

EPS Estimate

—

EPS Difference

—

Surprise Percent

undefined%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(4)
Quality
Moderate Quality(5.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

NOK 0

Cost Of Revenue

NOK 0

Gross Profit

NOK 0

Operating Expenses

NOK 0

Operating Income

NOK 0

Interest Expense

NOK 0

Pretax Income

NOK 0

Net Income

NOK 0

Income Tax Expense

NOK 0

EBITDA

NOK 0

Total Other Income Expense Net

NOK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

NOK 0

Short Term Investments

NOK 0

Receivables

NOK 0

Inventories

NOK 0

Total Current Assets

NOK 0

Property Plant Equipment

NOK 0

Total Assets

NOK 0

Payables

NOK 0

Short Term Debt

NOK 0

Long Term Debt

NOK 0

Total Liabilities

NOK 0

Equity

NOK 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

NOK 0

Depreciation

NOK 0

Change In Working Capital

NOK 0

Cash From Operations

NOK 0

Capital Expenditures

NOK 0

Cash From Investing

NOK 0

Cash From Financing

NOK 0

Net Change In Cash

NOK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.